Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma

被引:71
作者
Kondo, Naru [1 ]
Murakami, Yoshiaki [1 ]
Uemura, Kenichiro [1 ]
Sudo, Takeshi [1 ]
Hashimoto, Yasushi [1 ]
Sasaki, Hayato [1 ]
Sueda, Taijiro [1 ]
机构
[1] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Surg, Minami Ku, Hiroshima 7348551, Japan
关键词
cholangiocarcinoma; CA19-9; predictive marker; surgical resection; CHEMOTHERAPY IMPROVES SURVIVAL; SURGICAL RESECTION; ADJUVANT CHEMOTHERAPY; TUMOR-MARKERS; CA19-9; LEVELS; CANCER; GEMCITABINE; LEWIS; CHEMORADIATION; CLASSIFICATION;
D O I
10.1002/jso.23666
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives Identification of prognostic markers is important to establish a perioperative therapeutic strategy for resectable cholangiocarcinoma (CC). The aim of this study was to investigate whether perioperative serum carbohydrate antigen 19-9 (CA19-9) levels can predict survival of patients who underwent surgical resection for CC. Methods The study included 106 patients who underwent surgical resection for CC. Serum CA19-9 levels were measured preoperatively after biliary drainage and postoperatively about 4 weeks after surgery. The association of clinicopathological factors (including perioperative serum CA19-9 levels) with overall survival (OS) was analyzed with univariate and multivariate analyses. Results Differences in OS were significant between groups divided on the basis of two preoperative CA19-9 cutoff values (in U/ml) of 37 and 200 and three postoperative CA19-9 cutoff values (in U/ml) of 37, 100, and 200. In multivariate analysis, absence of postoperative adjuvant chemotherapy (P=0.002), lymph node metastasis (P=0.0002), preoperative CA19-9 (200IU/ml) (P=0.03), and postoperative CA19-9 (37IU/ml) (P<0.0001) were identified as independent predictors of poor OS. Conclusion Both pre- and postoperative serum CA19-9 levels predict the survival of patients with resectable CC, and may contribute to the establishment of a new therapeutic strategy. J. Surg. Oncol. 2014; 110:422-429. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:422 / 429
页数:8
相关论文
共 30 条
[1]   Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma [J].
Barton, Joshua G. ;
Bois, John P. ;
Sarr, Michael G. ;
Wood, Christina M. ;
Qin, Rui ;
Thomsen, Kristine M. ;
Kendrick, Michael L. ;
Farnell, Michael B. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (11) :2050-2058
[2]   Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704 [J].
Berger, Adam C. ;
Garcia, Miguel, Jr. ;
Hoffman, John P. ;
Regine, William F. ;
Abrams, Ross A. ;
Safran, Howard ;
Konski, Andre ;
Benson, Alan B., III ;
MacDonald, John ;
Willett, Christopher G. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) :5918-5922
[3]   Survival Analysis of Intrahepatic Cholangiocarcinoma After Resection [J].
Cho, Seong Yeon ;
Park, Sang-Jae ;
Kim, Seong Hoon ;
Han, Sung-Sik ;
Kim, Young-Kyu ;
Lee, Kwang-Woong ;
Lee, Soon-Ae ;
Hong, Eun Kyung ;
Lee, Woo Jin ;
Woo, Sang Myung .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (07) :1823-1830
[4]   Preoperative Serum CA 19-9 Level as a Predictive Factor for Recurrence after Curative Resection in Biliary Tract Cancer [J].
Chung, Moon Jae ;
Lee, Kyong Joo ;
Bang, Seungmin ;
Park, Seung Woo ;
Kim, Kyung Sik ;
Lee, Woo Jung ;
Song, Si Young ;
Chung, Jae Bock ;
Park, Jeong Youp .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (06) :1651-1656
[5]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[6]   Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma [J].
Ferrone, Cristina R. ;
Finkelstein, Dianne M. ;
Thayer, Sarah P. ;
Muzikansky, Alona ;
Fernandez-del Castillo, Carlos ;
Warshaw, Andrew L. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2897-2902
[7]   CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy [J].
Hartwig, Werner ;
Strobel, Oliver ;
Hinz, Ulf ;
Fritz, Stefan ;
Hackert, Thilo ;
Roth, Constanze ;
Buechler, Markus W. ;
Werner, Jens .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (07) :2188-2196
[8]   Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies [J].
Hatzaras, Ioannis ;
Schmidt, Carl ;
Muscarella, Peter ;
Melvin, W. Scott ;
Ellison, E. Christopher ;
Bloomston, Mark .
HPB, 2010, 12 (02) :134-138
[9]   Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma [J].
Hong, Seung-Mo ;
Pawlik, Timothy M. ;
Cho, HyungJun ;
Aggarwal, Bhuvnesh ;
Goggins, Michael ;
Hruban, Ralph H. ;
Anders, Robert A. .
SURGERY, 2009, 146 (02) :250-257
[10]   The prognostic and predictive value of serum CA19.9 in pancreatic cancer [J].
Humphris, J. L. ;
Chang, D. K. ;
Johns, A. L. ;
Scarlett, C. J. ;
Pajic, M. ;
Jones, M. D. ;
Colvin, E. K. ;
Nagrial, A. ;
Chin, V. T. ;
Chantrill, L. A. ;
Samra, J. S. ;
Gill, A. J. ;
Kench, J. G. ;
Merrett, N. D. ;
Das, A. ;
Musgrove, E. A. ;
Sutherland, R. L. ;
Biankin, A. V. .
ANNALS OF ONCOLOGY, 2012, 23 (07) :1713-1722